Gallant Pet, Inc.
Gallant offers ready-to-use stem cell therapies that help pets heal from within, restoring vitality and supporting longer, healthier lives.
Funding history
About Gallant Pet, Inc.
How much funding has Gallant Pet, Inc. raised?
Gallant Pet, Inc. has raised $35.6M in total funding. The most recent round was Series A.
Where is Gallant Pet, Inc. headquartered?
Gallant Pet, Inc. is headquartered in San Diego, CA.
What does Gallant Pet, Inc. do?
Gallant offers ready-to-use stem cell therapies that help pets heal from within, restoring vitality and supporting longer, healthier lives.
What problem does Gallant Pet, Inc. solve?
Most pet therapies only manage symptoms rather than treating disease at its source.
What's Gallant Pet, Inc.'s solution?
Gallant develops ready-to-use regenerative stem cell therapies for pets designed to reduce inflammation, restore tissue function, and support long-term recovery, moving through the FDA's structured approval pathway for conditions like feline gingivostomatitis and canine/feline osteoarthritis.
What makes Gallant Pet, Inc. different?
The company emphasizes therapies that are ready-to-use and easy for vets to administer (versus symptom-only management), backed by an FDA conditional approval pathway and coverage from outlets like the LA Times and TechCrunch, plus an $18M raise for manufacturing expansion.
What makes Gallant Pet, Inc. notable?
Backed by Maveron (the VC firm co-founded by former Starbucks CEO Howard Schultz) and BOLD Capital Partners, it is developing ready-to-use stem cell therapies for pets.
Leadership
❝ Cite this page
Free to use in articles, research, and reference works. Stable URL, will not change. Data on this page last updated August 26, 2026.